相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Colton J. Bracken et al.
NATURE CHEMICAL BIOLOGY (2021)
Oxford-AstraZeneca COVID-19 vaccine efficacy
Maria Deloria Knoll et al.
LANCET (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein
Sebastian Pomplun et al.
ACS CENTRAL SCIENCE (2021)
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu et al.
CELL HOST & MICROBE (2021)
Nebulised interferon beta-1a for patients with COVID-19 Comment
Nathan Peiffer-Smadja et al.
LANCET RESPIRATORY MEDICINE (2021)
Engineered trimeric ACE2 binds viral spike protein and locks it in Three-up conformation to potently inhibit SARS-CoV-2 infection
Liang Guo et al.
CELL RESEARCH (2021)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Cell entry mechanisms of SARS-CoV-2
Jian Shang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Discovery of Potent Cyclic Sulfopeptide Chemokine Inhibitors via Reprogrammed Genetic Code mRNA Display
Jason Johansen-Leete et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto et al.
NATURE (2020)
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang et al.
NATURE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2
Xiaoqiang Huang et al.
Aging-US (2020)
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Caleb P. Skipper et al.
ANNALS OF INTERNAL MEDICINE (2020)
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Christopher O. Barnes et al.
CELL (2020)
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
Yunlong Cao et al.
CELL (2020)
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
Jakob Kreye et al.
CELL (2020)
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
Shuo Du et al.
CELL (2020)
High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
Wei Li et al.
CELL (2020)
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Lihong Liu et al.
NATURE (2020)
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Jiangdong Huo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
A. B. Cavalcanti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Christopher O. Barnes et al.
NATURE (2020)
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Anum Glasgow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Christine Toelzer et al.
SCIENCE (2020)
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Longxing Cao et al.
SCIENCE (2020)
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
Jianbo Dong et al.
SCIENTIFIC REPORTS (2020)
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
Nicholas C. Wu et al.
CELL REPORTS (2020)
Human recombinant soluble ACE2 in severe COVID-19
Alexander Zoufaly et al.
LANCET RESPIRATORY MEDICINE (2020)
The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
Gideon Schreiber
FRONTIERS IN IMMUNOLOGY (2020)
Antibody-like proteins that capture and neutralize SARS-CoV-2
T. Kondo et al.
SCIENCE ADVANCES (2020)
Development of cyclic peptides with potent in vivo osteogenic activity through RaPID-based affinity maturation
Nasir K. Bashiruddin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Michael Schoof et al.
SCIENCE (2020)
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Yufei Xiang et al.
SCIENCE (2020)
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Thomas W. Linsky et al.
SCIENCE (2020)
Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor
Katsuya Sakai et al.
NATURE CHEMICAL BIOLOGY (2019)
De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains
Mickal Nawatha et al.
NATURE CHEMISTRY (2019)
Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides
Ziqing Qian et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2017)
Targeting Protein-Protein Interfaces Using Macrocyclic Peptides
Meng Gao et al.
BIOPOLYMERS (2015)
Macrocycles: lessons from the distant past, recent developments, and future directions
Andrei K. Yudin
CHEMICAL SCIENCE (2015)
DRUG DISCOVERY Tools and rules for macrocycles
Christian Heinis
NATURE CHEMICAL BIOLOGY (2014)
A Cyclic Peptide Inhibitor of HIF-1 Heterodimerization That Inhibits Hypoxia Signaling in Cancer Cells
Elena Miranda et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Bicyclic Peptide Inhibitor Reveals Large Contact Interface with a Protease Target
Alessandro Angelini et al.
ACS CHEMICAL BIOLOGY (2012)
Natural Product-Like Macrocyclic N-Methyl-Peptide Inhibitors against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed De Novo Library
Yusuke Yamagishi et al.
CHEMISTRY & BIOLOGY (2011)
The exploration of macrocycles for drug discovery - an underexploited structural class
Edward M. Driggers et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
分享论文
